(Q42663781)

4 November 2017

title

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis (English)

1 reference

4 November 2017

1 reference

Andrew J K Ostör

1

1 reference

4 November 2017

publication date

1 August 2008

1 reference

4 November 2017

published in

Clinical Rheumatology

1 reference

4 November 2017

volume

27

1 reference

4 November 2017

issue

11

1 reference

4 November 2017

page(s)

1343-1353

1 reference

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

4 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10067-008-0964-3

The epidemiology of autoimmune diseases

21 January 2018

1 reference

12 December 2020

Prevalence and predictors of ocular manifestations of RA: is there a need for routine screening?

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Symmetry of radiological features in the wrist and hands of patients with early to moderate rheumatoid arthritis: a quantitative microfocal radiographic study

1 reference

12 December 2020

Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome.

1 reference

12 December 2020

Skin disorders with arthritis

1 reference

12 December 2020

B cells move to centre stage: novel opportunities for autoimmune disease treatment

1 reference

12 December 2020

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

1 reference

12 December 2020

The role of novel T cell costimulatory pathways in autoimmunity and transplantation.

1 reference

12 December 2020

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis

1 reference

12 December 2020

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective

1 reference

12 December 2020

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

New therapies for treatment of rheumatoid arthritis

1 reference

12 December 2020

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial

1 reference

12 December 2020

Dendritic cells, chemokine receptors and autoimmune inflammatory diseases

1 reference

12 December 2020

Interstitial lung disease in rheumatoid arthritis: recent advances

1 reference

12 December 2020

The heart and cardiovascular manifestations in rheumatoid arthritis

1 reference

12 December 2020

Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab

1 reference

12 December 2020

Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity

1 reference

12 December 2020

Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis

1 reference

12 December 2020

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

12 December 2020

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

1 reference

12 December 2020

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

12 December 2020

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.

1 reference

12 December 2020

Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody

1 reference

12 December 2020

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

1 reference

12 December 2020

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system

1 reference

12 December 2020

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

1 reference

12 December 2020

Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis

1 reference

12 December 2020

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

12 December 2020

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

1 reference

12 December 2020

Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis.

1 reference

12 December 2020

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

1 reference

12 December 2020

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

12 December 2020

10.1007/S10067-008-0964-3

Identifiers

DOI

1 reference

4 November 2017

1 reference